[ENZN] Enzon Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization: 20.34 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.37 Change: 0.02 (4.29%)
Ext. hours: Change: 0 (0%)

chart ENZN

Refresh chart

Strongest Trends Summary For ENZN

ENZN is in the long-term up 4038% in 11 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Enzon Pharmaceuticals, Inc. is engaged in licensing drug products. Its marketed drug products include PegIntron for chronic hepatitis C; Sylatron for Melanoma; Macugen for neovascular age-related macular degeneration; CIMZIA for Crohn?s disease; Oncaspar for acute lymphoblastic leukemia; and Adagen for severe combined immunedeficiency. The company was founded in 1981 and is headquartered in Piscataway, New Jersey.

Fundamental Ratios
Shares Outstanding44.21 M EPS0.43 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y-134.02% Sales Growth - 4 Quarters -32.26% Sales Growth - Q/Q-16.07% P/E1.07
P/E To EPS Growth P/S0.74 P/BV0.58 Price/Cash Per Share
Price/Free Cash Flow ROA72.55% ROE74.65% ROI
Current Ratio49.77 Quick Ratio Long Term Debt/Equity Debt Ratio0.02
Gross Margin Operating Margin91.05% Net Profit Margin99.96% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-4.42 M Cash From Investing Activities Cash From Operating Activities4.67 M Gross Profit
Net Profit7.17 M Operating Profit4.68 M Total Assets37.83 M Total Current Assets35.29 M
Total Current Liabilities710 K Total Debt Total Liabilities1.06 M Total Revenue5.26 M
Technical Data
High 52 week0.27 Low 52 week0.17 Last close0.24 Last change0%
RSI42.86 Average true range0.01 Beta0.91 Volume111.91 K
Simple moving average 20 days-1.64% Simple moving average 50 days-3.3% Simple moving average 200 days8.94%
Performance Data
Performance Week0% Performance Month-7.69% Performance Quart4.35% Performance Half8.45%
Performance Year-8.05% Performance Year-to-date20.06% Volatility daily3.02% Volatility weekly6.76%
Volatility monthly13.85% Volatility yearly47.97% Relative Volume112.43% Average Volume21.28 K
New High New Low

News

2018-03-05 08:30:00 | Independent Research on Trending Growth Companies: Vet Online Supply and Enzon Pharmaceuticals

2017-09-29 08:44:56 | Enzon Pharmaceuticals, Inc. :ENZN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017

2017-05-18 10:38:30 | Enzon Pharmaceuticals, Inc. :ENZN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 18, 2017

2017-03-28 08:35:34 | Enzon Pharmaceuticals, Inc. :ENZN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 28, 2017

2017-03-24 16:11:54 | ENZON PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report

2017-03-04 19:25:01 | Icahn's Potential Move Into Biotech

2016-12-08 16:20:49 | ENZON PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events

2016-12-02 11:41:40 | Carl Icahn Takes 15% Stake in Enzon Pharmaceuticals

2016-11-15 06:12:11 | ENZON PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events

2016-11-14 12:09:41 | Enzon Pharmaceuticals, Inc. :ENZN-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016

2016-11-10 16:18:56 | ENZON PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report

2016-10-26 16:32:00 | ENZON PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events

2016-08-23 13:04:35 | ENZON PHARMACEUTICALS, INC. Financials

2016-08-12 11:40:47 | Enzon Pharmaceuticals, Inc. :ENZN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016

2016-08-10 17:41:02 | OTC Markets Group Welcomes Enzon Pharmaceuticals, Inc. to OTCQX

2016-08-10 17:03:59 | ENZON PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report

2016-08-09 16:35:45 | ENZON PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events

2016-08-09 07:00:00 | OTC Markets Group Welcomes Enzon Pharmaceuticals, Inc. to OTCQX

2016-07-05 06:12:08 | ENZON PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events

2016-05-26 12:38:44 | Enzon Pharmaceuticals, Inc. :ENZN-US: Earnings Analysis: Q1, 2016 By the Numbers : May 26, 2016

2016-05-16 17:02:17 | ENZON PHARMACEUTICALS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or

2016-05-09 17:56:57 | ENZON PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report

2016-03-24 11:33:23 | Enzon Pharmaceuticals, Inc. :ENZN-US: Earnings Analysis: 2015 By the Numbers

2016-03-21 16:16:38 | ENZON PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events

2016-02-23 16:56:59 | ENZON PHARMACEUTICALS INC Files SEC form 8-K, Other Events

2016-02-09 17:24:08 | ENZON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Sta

2016-01-27 12:23:00 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Delaware Law by the Board of Enzon Pharmaceuticals Inc.

2015-12-10 11:41:56 | Enzon Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers

2015-12-07 16:07:22 | ENZON PHARMACEUTICALS INC Files SEC form 8-K, Other Events

2015-12-03 06:06:38 | ENZON PHARMACEUTICALS INC Files SEC form 8-K, Other Events

2015-11-25 14:46:27 | What Do Hedge Funds Think of Enzon Pharmaceuticals, Inc. ENZN?

2015-11-12 06:04:48 | ENZON PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or S

2015-08-14 07:00:00 | Guidance & Quarterly Review on Four Biotech Companies

2015-07-06 16:31:57 | Enzon Pharmaceuticals Inc ENZN’s Shares Rally After Special Cash Dividend Announcement

2015-04-01 15:26:15 | Voltari Corp VLTC: Carl Icahn Stirring Yet Another Pot

2014-11-03 14:17:00 | DELiA*s Rebounds As Reports Suggest Delisting May Be Imminent

2014-09-15 16:43:00 | George Soros Picks KIOR, RSH, BIOL Soar On Monday